5-(2,3-difluorophenoxy)-1,3-dimethyl-1H-pyrazole-4-carboxylic acid | 1274631-47-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-(2,3-difluorophenoxy)-1,3-dimethyl-1H-pyrazole-4-carboxylic acid
• 英文别名: 5-(2,3-Difluorophenoxy)-1,3-dimethylpyrazole-4-carboxylic acid
• CAS: 1274631-47-8
• 化学式: C₁₂H₁₀F₂N₂O₃
• 分子量: 268.22
• InChiKey: LNCGHIFRZWTAGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-(2,3-difluorophenoxy)-1,3-dimethyl-1H-pyrazole-4-carboxylic acid 、 (±)-毒藜碱 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 [5-(2,3-Difluorophenoxy)-1,3-dimethylpyrazol-4-yl]-(2-pyridin-3-ylpiperidin-1-yl)methanone
  参考文献：
  名称：

  Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries

  摘要：

  Optimization of a high-throughput screening hit led to the discovery of a new series of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as highly potent agonists of TGR5. This novel chemotype was rapidly developed through iterative combinatorial library synthesis. It was determined that in vitro agonist potency correlated with functional activity data from human peripheral blood monocytes. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.076
• 作为产物：
  描述：

  2,3-二氟苯酚 在 potassium permanganate 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 32.0h， 生成 5-(2,3-difluorophenoxy)-1,3-dimethyl-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries

  摘要：

  Optimization of a high-throughput screening hit led to the discovery of a new series of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as highly potent agonists of TGR5. This novel chemotype was rapidly developed through iterative combinatorial library synthesis. It was determined that in vitro agonist potency correlated with functional activity data from human peripheral blood monocytes. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.076

文献信息

• [EN] PHARMACEUTICAL COMPOSITION<br/>[FR] COMPOSITION PHARMACEUTIQUE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2012039972A1

  公开（公告）日：2012-03-29

  The present invention provides compounds of Formula (I): along with pharmaceutical compositions containing the same, and methods of use thereof in subjects in need of treatment.

  本发明提供了公式（I）的化合物：以及包含它们的制药组合物，并在需要治疗的受试者中使用它们的方法。
• PHARMACEUTICAL COMPOSITION
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20140155452A1

  公开（公告）日：2014-06-05

  The present invention provides compounds of Formula I: along with pharmaceutical compositions containing the same, and methods of use thereof in subjects in need of treatment.

  本发明提供了I式化合物，以及含有该化合物的药物组合物，并且提供了在需要治疗的受体中使用该化合物的方法。
• US9000024B2
  申请人：——

  公开号：US9000024B2

  公开（公告）日：2015-04-07